Helixon Secures Nearly RMB 500 Million in Series A Funding to Advance AI-Driven Drug Discovery

Recently, Helixon announced the completion of a nearly 500 million yuan Series A round of financing. This round was led by Morningside Ventures, with participation from Gaorong Ventures, Neumann Capital, and three angel round investors: Xianghe Business Consulting (Beijing) Co., Ltd., GL Ventures, and Beijing Qingzhi Innovation Management Consulting Co., Ltd. Helixon will continue to focus on the AI + new drug development field, expand its team and business development, enhance AI high-performance computing capabilities, broaden high-throughput experimental platforms, and simultaneously advance pipeline self-research and external cooperation.

Helixon is committed to building the next-generation artificial intelligence scientific computing platform, combined with self-developed high-throughput biological experimental technology, to provide drug researchers with an intelligent system for molecular computing, simulation, and design in the microscopic world. In the field of new drug development, especially in large-molecule drug discovery, Helixon is innovatively developing efficient machine learning algorithms and data acquisition technologies to reconstruct the drug development process, greatly enhancing the speed and efficiency of new drug research and development. Since its establishment in June 2021, Helixon has consistently remained at the forefront of industry and scientific research. Currently, the company has developed several revolutionary innovative algorithms for protein drug design and modeling, which have been integrated with a high-throughput experimental platform, completing a highly efficient iterative closed-loop of AI design/experimental validation. As the platform technology gradually matures, Helixon has begun to deploy multiple large-molecule and immunotherapy R&D pipelines, with expectations to rapidly advance to the clinical stage. Since last year, Helixon has attracted numerous top experts and young scientists from both domestic and international fields of artificial intelligence research, structural biology, and disease research. World-leading technical capabilities, a strong R&D team, and a clear business model positioning have earned Helixon widespread recognition in the capital market, allowing this round of financing to be completed efficiently.

Morningside Ventures Partner Zhang Fei"Morningside Ventures is delighted to lead this round of financing. Dr. Peng Jian is a mission-driven entrepreneur we highly appreciate. He has gathered and led a group of top talents in the fields of science, algorithms, and engineering both in China and abroad, attempting to build a life science technology platform based on artificial intelligence. We wish Dr. Peng Jian and Helixon greater achievements in the future."

Gaorong Ventures Founding Partner Yue BinSaid, "After the emergence of AlphaFold2, we have been very concerned about the progress of artificial intelligence in the field of large-molecule new drug discovery. We look forward to the technical platform developed by Helixon helping scientists better analyze protein structures and interactions, facilitating the discovery of large-molecule drugs, and bringing benefits to patients."

Dr. Peng Jian, Founder of Helixon"Thank you to Morningside Ventures, Gaorong Ventures, Neumann Capital, and our existing shareholders for their full support of Helixon. This round of financing once again demonstrates the market's high recognition of Helixon's technology and business development. We will continue to move forward resolutely and quickly, increase investment in research and development, fully advance collaborations and pipeline development, and use artificial intelligence to safeguard human health."